EORTC Risk Model to Predict Progression in Patients With Non–Muscle-Invasive Bladder Cancer: Is It Safe to Use in Clinical Practice?

Babjuk, 2013, EAU Guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update, 2013, Eur Urol, 64, 639, 10.1016/j.eururo.2013.06.003 Colombel, 2008, Epidemiology, staging, grading, and risk stratification of bladder cancer, Eur Urol Suppl, 7, 618, 10.1016/j.eursup.2008.08.002 Van der Heijden, 2009, Recurrence, progression, and follow-up in non–muscle-invasive bladder cancer, Eur Urol Suppl, 8, 556, 10.1016/j.eursup.2009.06.010 Sylvester, 2006, Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, Eur Urol, 49, 466, 10.1016/j.eururo.2005.12.031 Kluth, 2015, Prognostic and prediction tools in bladder cancer: a comprehensive review of the literature, Eur Urol, 68, 238, 10.1016/j.eururo.2015.01.032 Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 Harrell, 1985, Regression models for prognostic prediction: advantages, problems, and suggested solutions, Cancer Treat Rep, 69, 1071 Seo, 2010, The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non–muscle-invasive bladder cancer after intravesical bacillus Calmette-Guérin instillation, Korean J Urol, 51, 165, 10.4111/kju.2010.51.3.165 Ather, 2009, Predicting recurrence and progression in non–muscle invasive bladder cancer using European Organization of Research and Treatment of Cancer risk tables, Urol J, 6, 189 Shariat, 2005, Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder, J Urol, 173, 1518 Vedder, 2014, Risk prediction scores for recurrence and progression of non–muscle invasive bladder cancer: an international validation in primary tumours, PLoS One, 9, e96849, 10.1371/journal.pone.0096849 Sylvester, 2011, How well can you actually predict which non–muscle-invasive bladder cancer patients will progress?, Eur Urol, 60, 431, 10.1016/j.eururo.2011.06.001 Fernandez-Gomez, 2011, The EORTC tables overestimate the risk of recurrence and progression in patients with non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables, Eur Urol, 60, 423, 10.1016/j.eururo.2011.05.033 Altman, 2009, Prognosis and prognostic research: validating a prognostic model, BMJ, 338, b605, 10.1136/bmj.b605 Hilden, 1978, The measurement of performance in probabilistic diagnosis. III. Methods based on continuous functions of the diagnostic probabilities, Methods Inf Med, 17, 238, 10.1055/s-0038-1636443 Hernández, 2011, External validation and applicability of the EORTC risk tables for non–muscle-invasive bladder cancer, World J Urol, 29, 409, 10.1007/s00345-010-0635-2 Van Rhijn, 2010, Molecular grade (FGFR3/MIB-1) and EORTC risk score are predictive in primary non–muscle-invasive bladder cancer, Eur Urol, 58, 433, 10.1016/j.eururo.2010.05.043 Lammers, 2014, Comparison of expected treatment outcome provided by risk models and international guidelines with observed treatment outcome in a cohort of Dutch non–muscle-invasive bladder cancer patients treated with intravesical chemotherapy, BJU Int, 114, 193, 10.1111/bju.12495 Ding, 2014, Are EORTC risk tables suitable for Chinese patients with nonmuscle-invasive bladder cancer?, Cancer Epidemiol, 38, 157, 10.1016/j.canep.2014.02.001 Xu, 2012, Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non¬muscle invasive bladder cancer after intravesical pirarubicin instillation, Zhonghua Zhong Liu Za Zhi, 34, 609 Altieri, 2012, Recurrence and progression in non–muscle-invasive bladder cancer using EORTC risk tables, Urol Int, 89, 61, 10.1159/000336516 Ajili, 2013, The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non–muscle-invasive bladder cancer treated by bacillus Calmette-Guérin immunotherapy, Ultrastruct Pathol, 37, 249, 10.3109/01913123.2013.786772 Pillai, 2011, Do standardised prognostic algorithms reflect local practice? Application of EORTC risk tables for non–muscle invasive (pTa/pT1) bladder cancer recurrence and progression in a local cohort, ScientificWorldJournal, 11, 751, 10.1100/tsw.2011.77 Xylinas, 2013, Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non–muscle-invasive urothelial carcinoma of the bladder, Br J Cancer, 109, 1460, 10.1038/bjc.2013.372 Borkowska, 2013, EORTC risk tables—their usefulness in the assessment of recurrence and progression risk in non–muscle-invasive bladder cancer in Polish patients, Cent Eur J Urol, 66, 14, 10.5173/ceju.2013.01.art5